Sequana Medical NV (EBR: SEQUA)
Belgium
· Delayed Price · Currency is EUR
0.894
+0.034 (3.95%)
Nov 20, 2024, 5:29 PM CET
Sequana Medical NV Company Description
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally.
The company products pipeline comprises alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body and heart failure.
Sequana Medical NV was founded in 2006 and is headquartered in Ghent, Belgium.
Sequana Medical NV
Country | Belgium |
Founded | 2006 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 62 |
CEO | Ian Crosbie |
Contact Details
Address: Kortrijksesteenweg 1112 Gent, 9051 Belgium | |
Phone | 32 9 298 28 28 |
Website | sequanamedical.com |
Stock Details
Ticker Symbol | SEQUA |
Exchange | Euronext Brussels |
Fiscal Year | January - December |
Reporting Currency | EUR |
ISIN Number | BE0974340722 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Ian Crosbie | Chief Executive Officer and Executive Director |
Kirsten Van Bockstaele | Chief Financial Officer |
Lies Vanneste | Director of Investor Relations |
Martijn Blom | Chief Commercial Officer |
Dr. Oliver Godje M.D., Ph.D. | Chief Medical Officer |